The Exchange had sought clarification from Ajooni Biotech Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech resubmitted its FY25 financial results to NSE in the correct machine-readable format after the exchange rejected the earlier filing for not following the prescribed SEBI format. For the full year ended March 2025, revenue from operations rose to Rs 11,469.19 lakhs from Rs 8,011.46 lakhs in FY24, a growth of about 43%. Net profit for the year stood at Rs 337.20 lakhs, up roughly 56% from Rs 216.12 lakhs in the previous year. The company raised Rs 4,231.49 lakhs through a rights issue at Rs 5 per share (including Rs 3 premium), which nearly doubled its equity share capital to Rs 3,444.87 lakhs. The statutory auditor issued an unmodified opinion, reported no fraud, and confirmed adequate internal financial controls with no going concern issues.
The strong FY25 revenue and profit growth, combined with the successful rights issue, is a positive signal for shareholders, though the diluted EPS dipped due to the expanded share base. The clean, unmodified audit opinion should restore confidence after the initial format-related exchange query.